Significant Stock Losses in PhaseRx, Inc. (PZRXQ) Sold By Laidlaw and Company

Soreide Law Group has been contacted by clients who purchased PhaseRx, Inc. (PZRXQ) and experienced significant stock losses through the sale of the stock brokers at Laidlaw and Company. Laidlaw is listed on their website as the “Book Runner” from the May 2016 offering. Securities that are newly issued are typically more volatile than the older more established companies, and if you, as the investor, were not looking to speculate, this could have been a highly unsuitable recommendation given to you by your broker from Laidlaw and Company.
According to Yahoo Finance, PhaseRx, Inc. (PZRXQ), is a biopharmaceutical company, engaging in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
In May of 2016, PhaseRx, Inc. (PZRXQ) was trading around 5.64, and today it is trading at approximately .005. The 52-week change is 99.15%.
On Laidlaw and Company’s website, the following information on their company is given: "Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you’ve experienced investment losses in PhaseRx, Inc. (PZRXQ) due to the recommendations of Laidlaw and Company’s securities brokers, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possible recovery of your valuable financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA.  We operate on a contingency fee basis, no fee if no recovery.